ArticleDiscover oncology2025
Diagnostic value of CD138 and GATA3 in benign prostatic hyperplasia and prostate cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analysis of risk factors for MRI-invisible prostate cancer-the significance of AGGF1 immunohistochemical detection and PSAD.The Canadian journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the diagnostic utility of GATA3 and CD138 as basal compartment markers in differentiating benign prostatic hyperplasia (BPH) from prostate cancer (PCa).
methodsImmunohistochemical analysis of GATA3, CD138, CK34βE12, and P63 was performed on 131 prostate tissue samples (77BPH,54PCa). Expression profiles, sensitivity, specificity, and Cohen's Kappa agreement were compared between markers.
resultsIn BPH samples, nuclear expression of GATA3 and p63 showed identical positive rates (92.21%, 95%CI: 89.3-94.8%), while CD138 (antibody concentration 1:200) and CK34βE12 (antibody concentration 1:100) demonstrated cytoplasmic/membranous positivity in 96.10% (93.4-98.1%) and 93.51% (90.2-95.9%) of cases respectively. All markers exhibited complete negativity (H-score < 5) in PCa basal cells.GATA3 achieved 100% diagnostic concordance (95%CI: 97.8-100%) with p63 in both BPH and PCa (perfect agreement, κ = 1, p < 0.001 by McNemar-Bowker test). Compared to CK34βE12:In BPH: Sensitivity = 98.61% (97.2-99.4%), Specificity = 100% (NPV 96.3%);In PCa: Diagnostic accuracy = 100% (AUC 1.0);(Inter-rater reliability κ = 0.902-1.0, weighted least squares method).CD138 achieved 100% analytic sensitivity but suboptimal specificity (57.1%, 95%CI: 44.8-68.7%) in BPH when referenced against p63/CK34βE12, while achieving perfect discrimination (κ = 0.926, p = 7.6 × 10
conclusionsGATA3 and CD138 demonstrate basal compartment enrichment patterns that complement conventional markers for PCa diagnosis (accuracy 96-100%). Their nuclear (GATA3) and cytoplasmic (CD138) localization enhances reliability, particularly in cases with fixation artifacts or ambiguous morphology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.